AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
nitric oxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1948 | 10102-43-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. It has been shown to have in vitro activity against severe acute res-piratory syndrome corona-virus (SARS-CoV-1) but evidence supporting the use of inhaled nitric oxide in COVID-19 patients is currently limited.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 23, 1999 | FDA | INO | |
| Aug. 1, 2001 | EMA | LINDE HEALTHCARE AB |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vitamin B1 decreased | 192.87 | 67.11 | 30 | 2988 | 508 | 90624921 |
| Blood lactic acid decreased | 183.57 | 67.11 | 28 | 2990 | 414 | 90625015 |
| Oxygen saturation decreased | 176.25 | 67.11 | 81 | 2937 | 107402 | 90518027 |
| Hypoxia | 175.78 | 67.11 | 72 | 2946 | 72327 | 90553102 |
| Cardiac output increased | 170.77 | 67.11 | 27 | 2991 | 510 | 90624919 |
| Intraventricular haemorrhage neonatal | 134.15 | 67.11 | 20 | 2998 | 251 | 90625178 |
| Product use issue | 130.93 | 67.11 | 99 | 2919 | 329820 | 90295609 |
| Patent ductus arteriosus | 123.55 | 67.11 | 29 | 2989 | 4540 | 90620889 |
| Hyperlactacidaemia | 115.77 | 67.11 | 27 | 2991 | 4109 | 90621320 |
| Pulmonary hypertensive crisis | 108.66 | 67.11 | 18 | 3000 | 459 | 90624970 |
| Vitamin B1 increased | 102.42 | 67.11 | 15 | 3003 | 165 | 90625264 |
| Device failure | 102.06 | 67.11 | 27 | 2991 | 6870 | 90618559 |
| Underdose | 98.77 | 67.11 | 44 | 2974 | 53973 | 90571456 |
| Electrocardiogram abnormal | 95.74 | 67.11 | 28 | 2990 | 10270 | 90615159 |
| Right ventricular failure | 94.01 | 67.11 | 32 | 2986 | 19173 | 90606256 |
| Bronchopulmonary dysplasia | 90.41 | 67.11 | 16 | 3002 | 608 | 90624821 |
| Premature delivery | 81.98 | 67.11 | 35 | 2983 | 38727 | 90586702 |
| Pulmonary hypertension | 78.87 | 67.11 | 35 | 2983 | 42488 | 90582941 |
| Pneumothorax | 78.64 | 67.11 | 28 | 2990 | 19139 | 90606290 |
| Pulmonary haemorrhage | 75.41 | 67.11 | 22 | 2996 | 7991 | 90617438 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product use issue | 358.74 | 57.44 | 145 | 2502 | 76606 | 42542082 |
| Oxygen saturation decreased | 182.78 | 57.44 | 86 | 2561 | 64601 | 42554087 |
| Device delivery system issue | 136.24 | 57.44 | 27 | 2620 | 1010 | 42617678 |
| No adverse event | 132.38 | 57.44 | 59 | 2588 | 38962 | 42579726 |
| Underdose | 126.15 | 57.44 | 45 | 2602 | 16621 | 42602067 |
| Device issue | 108.00 | 57.44 | 38 | 2609 | 13471 | 42605217 |
| Pulmonary hypertension | 97.40 | 57.44 | 41 | 2606 | 23528 | 42595160 |
| Product use in unapproved indication | 83.93 | 57.44 | 78 | 2569 | 184378 | 42434310 |
| Neonatal hypotension | 83.89 | 57.44 | 14 | 2633 | 194 | 42618494 |
| Respiratory failure | 80.10 | 57.44 | 65 | 2582 | 128067 | 42490621 |
| Condition aggravated | 79.87 | 57.44 | 89 | 2558 | 260665 | 42358023 |
| Drug ineffective | 79.55 | 57.44 | 140 | 2507 | 630057 | 41988631 |
| Device failure | 70.81 | 57.44 | 19 | 2628 | 2724 | 42615964 |
| Neonatal disorder | 70.61 | 57.44 | 15 | 2632 | 792 | 42617896 |
| Hypertrophic cardiomyopathy | 66.85 | 57.44 | 16 | 2631 | 1449 | 42617239 |
| Device malfunction | 66.54 | 57.44 | 26 | 2621 | 12301 | 42606387 |
| Pulmonary haemorrhage | 64.93 | 57.44 | 25 | 2622 | 11372 | 42607316 |
| Pulmonary hypertensive crisis | 63.25 | 57.44 | 11 | 2636 | 197 | 42618491 |
| Off label use | 59.60 | 57.44 | 125 | 2522 | 638210 | 41980478 |
| Right ventricular failure | 58.16 | 57.44 | 22 | 2625 | 9533 | 42609155 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product use issue | 443.22 | 54.92 | 218 | 3805 | 311477 | 110273799 |
| Oxygen saturation decreased | 219.49 | 54.92 | 109 | 3914 | 156873 | 110428403 |
| Vitamin B1 decreased | 173.48 | 54.92 | 30 | 3993 | 909 | 110584367 |
| Blood lactic acid decreased | 173.08 | 54.92 | 28 | 3995 | 560 | 110584716 |
| Hypoxia | 166.39 | 54.92 | 85 | 3938 | 129430 | 110455846 |
| Cardiac output increased | 164.88 | 54.92 | 27 | 3996 | 584 | 110584692 |
| Product use in unapproved indication | 158.04 | 54.92 | 130 | 3893 | 447247 | 110138029 |
| Right ventricular failure | 130.07 | 54.92 | 45 | 3978 | 25909 | 110559367 |
| Vitamin B1 increased | 101.08 | 54.92 | 15 | 4008 | 165 | 110585111 |
| Drug ineffective | 100.82 | 54.92 | 189 | 3834 | 1520351 | 109064925 |
| Respiratory failure | 100.56 | 54.92 | 74 | 3949 | 215258 | 110370018 |
| Cardiac arrest | 99.58 | 54.92 | 71 | 3952 | 196682 | 110388594 |
| Hyperlactacidaemia | 94.76 | 54.92 | 27 | 3996 | 8259 | 110577017 |
| Pulmonary hypertension | 94.04 | 54.92 | 44 | 3979 | 55176 | 110530100 |
| Off label use | 91.39 | 54.92 | 180 | 3843 | 1500005 | 109085271 |
| Pulmonary hypertensive crisis | 87.12 | 54.92 | 15 | 4008 | 442 | 110584834 |
| Device issue | 82.85 | 54.92 | 35 | 3988 | 34500 | 110550776 |
| Electrocardiogram abnormal | 80.59 | 54.92 | 29 | 3994 | 18680 | 110566596 |
| Device failure | 80.23 | 54.92 | 23 | 4000 | 7184 | 110578092 |
| Drug ineffective for unapproved indication | 78.47 | 54.92 | 48 | 3975 | 102790 | 110482486 |
| Premature delivery | 76.67 | 54.92 | 32 | 3991 | 30600 | 110554676 |
| Device delivery system issue | 69.37 | 54.92 | 16 | 4007 | 2117 | 110583159 |
| Pulmonary arterial pressure increased | 69.08 | 54.92 | 19 | 4004 | 5108 | 110580168 |
| Pulmonary arterial hypertension | 68.24 | 54.92 | 30 | 3993 | 32538 | 110552738 |
| Pulmonary congestion | 66.42 | 54.92 | 29 | 3994 | 30937 | 110554339 |
| Pulmonary haemorrhage | 65.26 | 54.92 | 24 | 3999 | 16432 | 110568844 |
| Condition aggravated | 63.40 | 54.92 | 103 | 3920 | 734733 | 109850543 |
| No adverse event | 62.88 | 54.92 | 37 | 3986 | 73802 | 110511474 |
| Pneumothorax | 56.61 | 54.92 | 27 | 3996 | 35258 | 110550018 |
| Hypotension | 55.75 | 54.92 | 81 | 3942 | 523768 | 110061508 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R07AX01 | RESPIRATORY SYSTEM OTHER RESPIRATORY SYSTEM PRODUCTS OTHER RESPIRATORY SYSTEM PRODUCTS Other respiratory system products |
| FDA PE | N0000009909 | Vasodilation |
| MeSH PA | D000975 | Antioxidants |
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D016166 | Free Radical Scavengers |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| MeSH PA | D045462 | Endothelium-Dependent Relaxing Factors |
| MeSH PA | D064426 | Gasotransmitters |
| FDA EPC | N0000175940 | Vasodilator |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:25512 | neurotransmitter |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35523 | bronchodilator agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:35718 | antifungal agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:48578 | radical scavenger |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:62488 | signalling molecule |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:70868 | antileishmanial agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:86327 | antifungal drug |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Related Drugs by ATC class:
R07AX Other respiratory system products 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pulmonary hypertension | indication | 70995007 | DOID:6432 |
| Persistent pulmonary hypertension of the newborn | indication | 233815004 | DOID:13042 |
| Methemoglobinemia | contraindication | 38959009 | DOID:10783 |
| Left heart failure | contraindication | 85232009 | |
| Congenital Heart Defect Requiring Open Patent Ductus Arteriosus | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 800PPM | GENOSYL | VERO BIOTECH INC | N202860 | Dec. 20, 2019 | RX | GAS | INHALATION | 8057742 | Jan. 18, 2026 | A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT |
| 800PPM | GENOSYL | VERO BIOTECH INC | N202860 | Dec. 20, 2019 | RX | GAS | INHALATION | 7947227 | Oct. 17, 2026 | A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8282966 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8293284 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8431163 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8795741 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8846112 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 4880PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Jan. 17, 2023 | RX | GAS | INHALATION | 11931377 | June 30, 2029 | A METHOD FOR TREATING A PEDIATRIC PATIENT WHO IS EXPERIENCING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION RESULTING IN OXYGEN DESATURATION, WHEREIN THE PATIENT IS NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING OF BLOOD |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 11931377 | June 30, 2029 | A METHOD FOR TREATING A PEDIATRIC PATIENT WHO IS EXPERIENCING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION RESULTING IN OXYGEN DESATURATION, WHEREIN THE PATIENT IS NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING OF BLOOD |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8282966 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8293284 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8431163 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8795741 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8846112 | June 30, 2029 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| 800PPM | GENOSYL | VERO BIOTECH INC | N202860 | Dec. 20, 2019 | RX | GAS | INHALATION | 9604028 | Aug. 13, 2029 | A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8291904 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8573210 | Jan. 6, 2031 | A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8776794 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | DISCN | GAS | INHALATION | 8776795 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8291904 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8573210 | Jan. 6, 2031 | A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8776794 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 8776795 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 9265911 | Jan. 6, 2031 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 9295802 | Jan. 6, 2031 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 9408993 | Jan. 6, 2031 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 9279794 | Feb. 19, 2035 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT |
| 800PPM | INOMAX | MALLINCKRODT IRELAND | N020845 | Dec. 23, 1999 | RX | GAS | INHALATION | 9770570 | May 3, 2036 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE |
| 800PPM | GENOSYL | VERO BIOTECH INC | N202860 | Dec. 20, 2019 | RX | GAS | INHALATION | 11672938 | July 22, 2040 | A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Soluble guanylate cyclase | Enzyme | ACTIVATOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 31C4KY9ESH | UNII |
| 4021248 | VUID |
| N0000148689 | NUI |
| D00074 | KEGG_DRUG |
| 4021248 | VANDF |
| C0028128 | UMLSCUI |
| CHEBI:16480 | CHEBI |
| NO | PDB_CHEM_ID |
| CHEMBL1200689 | ChEMBL_ID |
| 145068 | PUBCHEM_CID |
| DB00435 | DRUGBANK_ID |
| D009569 | MESH_DESCRIPTOR_UI |
| 405139 | RXNORM |
| 17479 | MMSL |
| 47106 | MMSL |
| d04508 | MMSL |
| 012088 | NDDF |
| 409378005 | SNOMEDCT_US |
| 6710000 | SNOMEDCT_US |
| 31C4KY9ESH | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Noxivent 102 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59579-102 | GAS | 800 mg | RESPIRATORY (INHALATION) | ANDA | 16 sections |
| INOMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64693-002 | GAS | 0.98 mg | RESPIRATORY (INHALATION) | NDA | 23 sections |
| INOMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64693-003 | GAS | 6 mg | RESPIRATORY (INHALATION) | NDA | 23 sections |
| Nitric Oxide Nitrogen Mix | HUMAN PRESCRIPTION DRUG LABEL | 2 | 67989-011 | GAS | 5 mL | RESPIRATORY (INHALATION) | unapproved medical gas | 1 sections |
| GENOSYL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72385-001 | GAS | 0.98 mg | RESPIRATORY (INHALATION) | NDA | 23 sections |
| GENOSYL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72385-002 | GAS | 0.98 mg | RESPIRATORY (INHALATION) | NDA | 26 sections |
| GENOSYL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72385-003 | GAS | 0.98 mg | RESPIRATORY (INHALATION) | NDA | 26 sections |
| Noxivent | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72385-102 | GAS | 800 mg | RESPIRATORY (INHALATION) | ANDA | 16 sections |
| NOW st | HUMAN OTC DRUG LABEL | 1 | 80519-301 | LIQUID | 1.12 g | TOPICAL | unapproved drug other | 12 sections |
| Ulspira | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82605-006 | GAS | 0.80 mL | RESPIRATORY (INHALATION) | ANDA | 15 sections |
| Ulspira | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82605-008 | GAS | 0.80 mL | RESPIRATORY (INHALATION) | ANDA | 2 sections |